NFκB activity in Tax transgenic mouse tissues
Treatment . | Mean NFκB activity in vivo, OD ± SEM* . | Inhibition of NFκB activity in vitro† . |
|---|---|---|
| Vehicle-treated Tax+ tumors | 0.270 ± 0.084 | Tumor progressors, 1% |
| PS-341–treated Tax+ tumors | 0.312 ± 0.120 | Tumor progressors, 0%-28% |
| Stable/remissions/nonprogressors, 92%-99% |
Treatment . | Mean NFκB activity in vivo, OD ± SEM* . | Inhibition of NFκB activity in vitro† . |
|---|---|---|
| Vehicle-treated Tax+ tumors | 0.270 ± 0.084 | Tumor progressors, 1% |
| PS-341–treated Tax+ tumors | 0.312 ± 0.120 | Tumor progressors, 0%-28% |
| Stable/remissions/nonprogressors, 92%-99% |
OD indicates optical density.
Nuclear extracts were prepared from 8 PS-341–treated tumors and 5 vehicle-treated tumors, and p50-p65 NFκB DNA-binding activity was measured in ELISA format as described in “Materials and methods”
Cells from tissues were cultured in the presence of PS-341 for 20 hours, and NFκB activity was determined using p65 ELISA. Percent inhibition in both groups corresponding to status of disease is listed